World Health Organization Guidelines Highlight Lack of Data on Ozempic Use for Postpartum Women
The World Health Organization (WHO) recently released its first guidelines on the use of GLP-1 receptor agonists, such as Ozempic, generically known as semaglutide. These guidelines advise against prescribing GLP-1s to pregnant women but do not address their use by postpartum women, including those who are breastfeeding. This omission has left new mothers, like Sara, who are dealing with postpartum weight gain, without clear guidance on the safety of using Ozempic. The lack of data on the long-term effects and safety of Ozempic in postpartum women is a significant concern, as highlighted by clinical psychologist Nicole Amoyal Pensak. The popularity of GLP-1s for weight loss among new mothers is rising, despite the unknowns regarding their impact on maternal brain rewiring and infant health. 
